Cargando…

Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel

BACKGROUND: The landscape for hemophilia A prophylaxis is rapidly expanding from factor VIII replacement therapy to include novel treatments such as nonfactor replacement therapies that may enhance coagulation (e.g., emicizumab) or inhibit anticoagulant pathways (e.g., fitusiran and concizumab). For...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Marlon, Tuly, Rifat, Harley, Carolyn, Pednekar, Priti, Batt, Katharine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394196/ https://www.ncbi.nlm.nih.gov/pubmed/33843253 http://dx.doi.org/10.18553/jmcp.2021.20600

Ejemplares similares

A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors
por: Veeranki, Sreenivas P, et al.
Publicado: (2021)

Private Payer Coverage Policies for ApoE-e4 Genetic Testing
por: Arias, Jalayne J., et al.
Publicado: (2021)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies
por: Chambers, James D., et al.
Publicado: (2018)

Value of a cure for sickle cell disease in reducing economic disparities
por: Graf, Marlon, et al.
Publicado: (2022)

Correction: Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs
por: Chambers, James D., et al.
Publicado: (2016)

Private Payer Coverage Policies for Whole Exome Sequencing (WES) in Pediatric Patients: Trends Over Time and Analysis of Evidence Cited
por: Douglas, Michael P., et al.
Publicado: (2018)

Association of opioid fills with centers for disease control and prevention opioid guidelines and payer coverage policies: physician, insurance and geographic factors
por: Togun, Adeniyi T., et al.
Publicado: (2021)

Variability in Private Payer Medical Policies for Osteochondral Allograft Transplantation Demonstrates the Absence of Standardization in Medical Criteria Between Payers
por: Tabbaa, Suzanne M., et al.
Publicado: (2022)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
por: Batt, Katharine, et al.
Publicado: (2019)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio
por: Molfenter, Todd, et al.
Publicado: (2018)

US public and private payer coverage for tobacco cessation treatments and barriers to accessing treatments
por: Hussain, Radha, et al.
Publicado: (2022)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Barriers to clinical adoption of next generation sequencing: Perspectives of a policy Delphi panel
por: Messner, Donna A., et al.
Publicado: (2016)

The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians
por: Sommariva, Silvia, et al.
Publicado: (2016)

Schizophrenia population health management: perspectives of and lessons learned from population health decision makers
por: Roach, Meaghan, et al.
Publicado: (2021)

Commercial and public payer opioid analgesic prescribing policies: a case study
por: Arfken, Cynthia L., et al.
Publicado: (2021)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

1278. Assessing Statewide HIV Pre-exposure Prophylaxis Implementation Using an All Payer Claims Database
por: Nocka, Kristen, et al.
Publicado: (2019)

Hospitals and the Tax-Payer
Publicado: (1920)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective
por: Baker, Christine L, et al.
Publicado: (2018)

Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study
por: Wang, Michael, et al.
Publicado: (2017)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
por: Shrestha, Anshu, et al.
Publicado: (2020)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
por: Jackson, Shannon C, et al.
Publicado: (2015)

Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity
por: Wang, Michael, et al.
Publicado: (2020)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

A Private Payer Persective
por: Shurney, Dexter W.
Publicado: (2006)

The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study
por: Armeni, Patrizio, et al.
Publicado: (2015)

Exploring HPV vaccination policy and payer strategies for opportunities to improve uptake in safety-net settings
por: Sloan, Kylie, et al.
Publicado: (2023)

Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration
por: Manolis, Chronis H., et al.
Publicado: (2016)

Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study
por: Batt, Katharine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kshcbb78ndm4i7eokc0oobkeje